Upstream Bio's CEO Rand Sutherland discusses today's severe asthma data for verekitug, a TSLP receptor antagonist
BiotechTV - News
00:00
Top-line phase 2 severe asthma results
Rand summarizes phase 2 valiant trial results, dosing regimens tested, and efficacy highlights versus placebo.
Play episode from 01:26
Transcript
